Samra Turajlic

List of Publications by Year
in descending order

94 papers	12,797 citations	70961 41 h-index	45213 90 g-index
107 all docs	107 docs citations	107 times ranked	19940 citing authors

#	Article	IF	Citations
1	Predictive biomarkers for response to immune checkpoint inhibition. Seminars in Cancer Biology, 2022, 79, 4-17.	4.3	70
2	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet, The, 2022, 399, 905-907.	6.3	60
3	Metastasis and organotropism: A look through the lens of large-scale clinical sequencing data. Cancer Cell, 2022, 40, 134-135.	7.7	1
4	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell, 2022, 40, 114-116.	7.7	50
5	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology, 2022, 19, 385-401.	12.5	135
6	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	3.4	30
7	Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Human Molecular Genetics, 2022, 31, 3001-3011.	1.4	9
8	The Genetic Evolution of Metastasis. Cancer Research, 2022, 82, 1849-1857.	0.4	10
9	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	1.6	4
10	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology, 2022, 81, 426-438.	1.6	39
11	The status of tumor mutational burden and immunotherapy. Nature Cancer, 2022, 3, 652-656.	5.7	48
12	Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188759.	3.3	1
13	The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part A: Renal, Penile, and Testicular Tumours. European Urology, 2022, 82, 458-468.	0.9	212
14	Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution. Clinical and Experimental Dermatology, 2021, 46, 338-341.	0.6	5
15	Summary from the Kidney Cancer Associationâ€™s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer, 2021, 19, 167-175.	0.9	4
16	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell, 2021, 184, 596-614.e14.	13.5	485
17	Tracking Cancer Evolution through the Disease Course. Cancer Discovery, 2021, 11, 916-932.	7.7	77
18	SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay. Wellcome Open Research, 2021, 6, 9.	0.9	13

#	Article	IF	Citations
19	Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution, 2021, 5, 1033-1045.	3.4	50
20	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nature Medicine, 2021, 27, 1362-1366.	15.2	70
21	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. , 2021, 9, e002835.		11
22	Immunotherapy use outside clinical trial populations: never say never?. Annals of Oncology, 2021, 32, 866-880.	0.6	22
23	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
24	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. Journal of Hepatology, 2021, 75, 177-189.	1.8	29
25	A protocol for representative sampling of solid tumors to improve the accuracy of sequencing results. STAR Protocols, 2021, 2, 100624.	0.5	5
26	Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. European Journal of Cancer, 2021, 156, 187-189.	1.3	2
27	Evolution of Renal Cell Carcinoma. European Urology Focus, 2021, 7, 148-151.	1.6	14
28	SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay. Wellcome Open Research, 2021, 6, 9.	0.9	11
29	Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. Journal of Endocrinological Investigation, 2021, 44, 195-203.	1.8	11
30	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	5.7	66
31	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	5.7	123
32	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	7.7	126
33	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 561-570.	1.0	43
34	Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study. Cell, 2020, 183, 4-10.	13.5	40
35	Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis. Journal of Immunotherapy, 2020, 43, 250-255.	1.2	11
36	Identification of conserved evolutionary trajectories in tumors. Bioinformatics, 2020, 36, i427-i435.	1.8	9

#	Article	IF	Citations
37	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications, 2020, 11, 3800.	5.8	61
38	How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open, 2020, 4, e000540.	2.0	25
39	Pervasive chromosomal instability and karyotype order in tumour evolution. Nature, 2020, 587, 126-132.	13.7	221
40	Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open, 2020, 5, e000585.	2.0	23
41	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. The Lancet Gastroenterology and Hepatology, 2020, 5, 679-697.	3.7	33
42	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	2.9	51
43	New survival standards for advanced melanoma. British Journal of Cancer, 2020, 122, 1275-1276.	2.9	12
44	Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products. Cancer Research, 2020, 80, 875-875.	0.4	2
45	Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTMmanufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use. , 2020, , .		0
46	Abstract PO-091: CAPTURE: Cancer and COVID-19 antiviral immune monitoring study. , 2020, , .		0
47	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
48	Standing on the shoulders of giants. Nature Medicine, 2019, 25, 357-357.	15.2	1
49	Resolving genetic heterogeneity in cancer. Nature Reviews Genetics, 2019, 20, 404-416.	7.7	443
50	Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma. Annals of Oncology, 2019, 30, 355-357.	0.6	2
51	Tumour mutational burden: primary versus metastatic tissue creates systematic bias. Immuno-Oncology Technology, 2019, 4, 8-14.	0.2	26
52	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell, 2018, 173, 611-623.e17.	13.5	398
53	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, 2018, 173, 595-610.e11.	13.5	472
54	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, 2018, 173, 581-594.e12.	13.5	609

#	Article	IF	Citations
55	First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. Annals of Oncology, 2018, 29, 542-543.	0.6	16
56	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell, 2018, 33, 649-663.e4.	7.7	448
57	Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. ESMO Open, 2018, 3, e000317.	2.0	12
58	PTU-009â€…Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea. , 2018, , .		2
59	PWE-025â€…Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis. , 2018, , .		1
60	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIVÂor hepatitis B/C infection. European Journal of Cancer, 2018, 104, 137-144.	1.3	97
61	Kidney cancer: The next decade. Journal of Experimental Medicine, 2018, 215, 2477-2479.	4.2	125
62	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877742.	1.4	7
63	Immunotherapy for Melanoma Metastatic to the Brain. New England Journal of Medicine, 2018, 379, 789-790.	13.9	7
64	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	6.6	323
65	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	13.7	1,287
66	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	13.9	1,786
67	Implications of cancer evolution for drug development. Nature Reviews Drug Discovery, 2017, 16, 441-442.	21.5	28
68	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	13.5	968
69	The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. Cancer Discovery, 2017, 7, 796-798.	7.7	14
70	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncology, The, 2017, 18, 1009-1021.	5.1	716
71	Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer Immunology, Immunotherapy, 2017, 66, 113-117.	2.0	31
72	Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Annals of Oncology, 2017, 28, 377-385.	0.6	215

#	Article	IF	Citations
73	Systemic treatment of advanced papillary renal cell carcinoma: Where next?. European Journal of Cancer, 2016, 69, 223-225.	1.3	1
74	Metastasis as an evolutionary process. Science, 2016, 352, 169-175.	6.0	497
75	Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Annals of Oncology, 2016, 27, 1135-1137.	0.6	131
76	ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS4583-TPS4583.	0.8	4
77	How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. Current Opinion in Urology, 2015, 25, 358-366.	0.9	34
78	SnapShot: Renal Cell Carcinoma. Cell, 2015, 163, 1556-1556.e1.	13.5	50
79	Inferring mutational timing and reconstructing tumour evolutionary histories. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 264-275.	3.3	48
80	Tracking tumour evolution through liquid biopsy. Nature Reviews Clinical Oncology, 2015, 12, 565-566.	12.5	4
81	Relapse models for clear cell renal carcinoma. Lancet Oncology, The, 2015, 16, e376-e378.	5.1	3
82	BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling. Science Signaling, 2014, 7, ra30.	1.6	113
83	Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Annals of Oncology, 2014, 25, 959-967.	0.6	53
84	The mutational burden of acral melanoma revealed by wholeâ€genome sequencing and comparative analysis. Pigment Cell and Melanoma Research, 2014, 27, 835-838.	1.5	108
85	Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. Journal of Pathology, 2013, 230, 261-269.	2.1	180
86	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. Cancer Discovery, 2013, 3, 158-167.	7.7	300
87	Phase I/II RAF kinase inhibitors in cancer therapy. Expert Opinion on Investigational Drugs, 2013, 22, 739-749.	1.9	11
88	SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma. Cancer Discovery, 2013, 3, 1122-1129.	7.7	358
89	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Therapeutic Advances in Medical Oncology, 2013, 5, 105-118.	1.4	45
90	Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Research, 2012, 22, 196-207.	2.4	155

#	Article	IF	Citations
91	A wholeâ€genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptorâ€negative and â€positive breast cancers. Journal of Pathology, 2012, 227, 29-41.	2.1	58
92	Genomic characterisation of acral melanoma cell lines. Pigment Cell and Melanoma Research, 2012, 25, 488-492.	1.5	46
93	Generalized melanosis and melanuria in a patient with metastatic melanoma. Clinical and Experimental Dermatology, 2010, 35, e37-e39.	0.6	10
94	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. SSRN Electronic Journal, 0, , .	0.4	2